Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Factors impacting treatment choice with a CD38 antibody, immunomodulator, proteasome inhibitor, and dexamethasone in first line multiple myeloma patients: A real-world US study

Joseph Franz, Joseph Mikhael, Dhaval Mehta, Rushir Choksi, Taya Salman, Mike Gart, John Li, Harshal Dave, Lisa Kunst, Kristen Henn, Prashanth Jain, Brandon Wang, Prateesh Varughese, Lisa Morere, Jeffrey Scott, Paul Richardson

Blood (2025) 146 (Supplement 1): 3988.

https://doi.org/10.1182/blood-2025-3988

Published: 2025

Journal Articles

Reveal-MM: Retrospective evaluation of variables in early assessment and landmark trends in multiple myeloma – a US claims-based case-control study

Faith Davies, Beth Faiman, Hayley Beer, Anne-Quinn Young, Katie Joyner, Kate Morgan, Stephen Huo, J Blake Bartlett, Yi Han, Georgia Attfield, Daniel Egbase, Joseph Mikhael

Blood (2025) 146 (Supplement 1): 4569.

https://doi.org/10.1182/blood-2025-4569

Published: 2025

Journal Articles

Charlotte African American MGUS project (CHAAMP): A prospective pilot study of MGUS screening in black and/or African American adults

Manisha Bhutani, Myra Robinson, Margarita Dzhanumova, Samantha Bradley, Adrienne Dobbins, Robin Cox, David Foureau, Shebli Atrash, Barry Paul, Cindy Varga, Christopher Ferreri, Reed Friend, Mauricio Pineda-Roman, Brittany Neelands, Joseph Mikhael, Nadine Barrett, Peter Voorhees

Blood (2025) 146 (Supplement 1): 8244.

https://doi.org/10.1182/blood-2025-8244

Published: 2025

Journal Articles

Down with dex!

Susan Harding, Joseph Mikhael

Blood (2025) 145 (1): 3–4.

https://doi.org/10.1182/blood.2024026814

Published: 2025

Journal Articles

Advancing Patient-Centered Care to Overcome Health Disparities in Multiple Myeloma: Key Findings from a Quality Improvement Initiative

Joseph Mikhael, Cesar Rodriguez, Amy E. Pierre, M. Sarfraz Nawaz, Ellie Moses-Okwei, Lindsay Gurska, Emily Zyborowicz, Shelby Sullivan, Jeffrey Carter, Cherilyn Heggen

Blood (2024) 144 (Supplement 1): 5034.

https://doi.org/10.1182/blood-2024-203674

Published: 2024

Journal Articles

Evidence of Improved Knowledge and Skills Among Hematologists/Oncologists Participating in Online CME-Certified Activities

Lauren Willis, Emily S. Van Laar, Tristin Abair, Megan Whitney, Caitlin Costello, Amrita Y. Krishnan, Sagar Lonial, Sandra Kurtin, Joseph Mikhael, Ola Landgren

Blood (2021) 138 (Supplement 1): 4958.

https://doi.org/10.1182/blood-2021-145375

Published: 2021

Journal Articles

High-Risk Gene Expression Subtype Provides Molecular Basis for Different Clinical Presentation of Primary and Secondary Plasma Cell Leukemia

Sheri Skerget, Daniel Penaherrera, Joseph Mikhael, Jonathan J Keats

Blood (2021) 138 (Supplement 1): 726.

https://doi.org/10.1182/blood-2021-148138

Published: 2021

Journal Articles

Pilot Trial of the My Hematology Oncology Patient Experience (MyHOPE™) for Multiple Myeloma (MM) Digital Solution in Patients with MM

Noopur S. Raje, MD, Omar Nadeem, MD, Joseph Mikhael, MD FRCPC, MD, Catherine Ludwig, MB BChir, Amit Agarwal, MD PhD, Judith Inumerable, PGC, Teng J. Ong, MD, Sundar Jagannath, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-141591

Published: 2020

Journal Articles

Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis

Thomas Martin, MD, Joseph Mikhael, MD FRCPC, MD, Roman Hajek, MD, Kihyun Kim, MD PhD, Kenshi Suzuki, MD PhD, Cyrille Hulin, MD, Mamta Garg, MD FRCP, FRCPath, Hang Quach, MDFRACP,FRCPA,MBBS, Hanlon Sia, Anup George, Tatiana Konstantinova, MD PhD, Marie-Laure Risse, Gaelle Asset, Sandrine Macé, Helgi van de Velde, MD PhD, Philippe Moreau, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-137681

Published: 2020

Journal Articles

Real-World Renal Function Among Patients with Multiple Myeloma in the United States

Joseph Mikhael, MD FRCPC, MD, Erin Singh, Megan Rice, ScD, MPH

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-136630

Published: 2020

Journal Articles

Understanding Root Causes Contributing to Real-World Racial Disparities in Multiple Myeloma Care: Insights from a Mixed-Methods Study Utilizing Tethered Patient-Provider Surveys and Chart Reviews

Joseph Mikhael, MD FRCPC, MD, Anne Jacobson, MS, Jeffrey D Carter, PhD, Tamar Sapir, PhD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-136750

Published: 2020

Journal Articles

The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study

Blood (2019) 134 (Supplement_1): 412.

https://doi.org/10.1182/blood-2019-126837

Published: 2019

Journal Articles

The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 Studies

Paul G. Richardson, MD, Joseph Mikhael, MD FRCPC, MD, Thierry Facon, MD, William I. Bensinger, Sandrine Macé, Marielle Chiron, Helgi van de Velde, MD PhD, Frank Campana, MD, Li Liu, Michel Attal, MD PhD

Blood (2019) 134 (Supplement_1): 3179.

https://doi.org/10.1182/blood-2019-128071

Published: 2019

Journal Articles

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

Joseph Mikhael, Paul Richardson, Saad Z. Usmani, Noopur Raje, William Bensinger, Chatchada Karanes, Frank Campana, Dheepak Kanagavel, Franck Dubin, Qianying Liu, Dorothée Semiond, Kenneth Anderson

Blood (2019) 134 (2): 123–133.

https://doi.org/10.1182/blood-2019-02-895193

Published: 2019

Journal Articles

Predicting Risk of Venous Thromboembolism in Multiple Myeloma: The Impede VTE Score

Kristen M. Sanfilippo, MD, Suhong Luo, MS, Tzu-Fei Wang, MD, Tanya Wildes, MD, Joseph Mikhael, MD FRCPC, MD, Jesse W. Keller, MD MPHS, Theodore S. Thomas, MD MPHS, Kenneth R. Carson, MD PhD, Brian F. Gage, MD MSc

Blood (2018) 132 (Supplement 1): 141.

https://doi.org/10.1182/blood-2018-99-116300

Published: 2018

Journal Articles

Patient Treatment Preferences for Relapsed/Refractory Multiple Myeloma: Are Patients Willing to Trade Off Efficacy for Tolerability?

Daniel Auclair, PhD, Carol Mansfield, PhD, Ajai Chari, MD, Craig E. Cole, MD, Mark A. Fiala, BS, Jonathan L Kaufman, MD, Gregory Orloff, MD, David S Siegel, MD PhD, Jeffrey A Zonder, MD, Brennan Mange, Jennifer Yesil, MS, Mehul Dalal, PhD, Joseph Mikhael, MD FRCPC, MD

Blood (2018) 132 (Supplement 1): 614.

https://doi.org/10.1182/blood-2018-99-113087

Published: 2018

Journal Articles

Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Paul G Richardson, MD, Joseph Mikhael, MD, Saad Z Usmani, MD, Noopur Raje, MD, William Bensinger, MD, Dheepak Kanagavel, MD PhD, Lei Gao, Samira Ziti-Ljajic, Kenneth C Anderson, MD

Blood (2017) 130 (Supplement 1): 1887.

https://doi.org/10.1182/blood.V130.Suppl_1.1887.1887

Published: 2017

Journal Articles

Understanding the Preferences of Patients and Caregivers for Relapsed/Refractory Multiple Myeloma Treatment: A Mixed-Mode Patient-Centric Approach

Daniel Auclair, PhD, Carol Mansfield, PhD, Ajai Chari, MD, Craig E. Cole, MD, Mark A. Fiala, BS, Jonathan L. Kaufman, MD, Gregory Orloff, MD, David Siegel, MD PhD, Jeff A. Zonder, MD, Brennan Mange, Jennifer Yesil, MS, Mehul Dalal, PhD, Joseph Mikhael, MD

Blood (2017) 130 (Supplement 1): 5662.

https://doi.org/10.1182/blood.V130.Suppl_1.5662.5662

Published: 2017

Journal Articles

Determinants of Hematology-Oncology Trainee's Post-Fellowship Career Pathways with a Focus on Non-Malignant Hematology

Ariela L. Marshall, MD, Sarah Jenkins, MS, Joseph Mikhael, MD MD FRCPC, Scott D. Gitlin, MD

Blood (2017) 130 (Supplement 1): 3365.

https://doi.org/10.1182/blood.V130.Suppl_1.3365.3365

Published: 2017

Journal Articles

Relapsed or Refractory Multiple Myeloma Patients Treated with Second-Line Carfilzomib and Categorized By Prior Exposure to Bortezomib: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials

Maria-Victoria Mateos, Hartmut Goldschmidt, MD, Jesus F San Miguel, MD PhD, Joseph Mikhael, MD, Lifen Zhou, Mihaela Obreja, Julie Blaedel, Karim Saad Iskander, Xavier Leleu, MD PhD

Blood (2017) 130 (Supplement 1): 1840.

https://doi.org/10.1182/blood.V130.Suppl_1.1840.1840

Published: 2017

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Factors impacting treatment choice with a CD38 antibody, immunomodulator, proteasome inhibitor, and dexamethasone in first line multiple myeloma patients: A real-world US study

Reveal-MM: Retrospective evaluation of variables in early assessment and landmark trends in multiple myeloma – a US claims-based case-control study

Charlotte African American MGUS project (CHAAMP): A prospective pilot study of MGUS screening in black and/or African American adults

Down with dex!

Advancing Patient-Centered Care to Overcome Health Disparities in Multiple Myeloma: Key Findings from a Quality Improvement Initiative

Evidence of Improved Knowledge and Skills Among Hematologists/Oncologists Participating in Online CME-Certified Activities

High-Risk Gene Expression Subtype Provides Molecular Basis for Different Clinical Presentation of Primary and Secondary Plasma Cell Leukemia

Pilot Trial of the My Hematology Oncology Patient Experience (MyHOPE™) for Multiple Myeloma (MM) Digital Solution in Patients with MM

Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis

Real-World Renal Function Among Patients with Multiple Myeloma in the United States

Understanding Root Causes Contributing to Real-World Racial Disparities in Multiple Myeloma Care: Insights from a Mixed-Methods Study Utilizing Tethered Patient-Provider Surveys and Chart Reviews

The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study

The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 Studies

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

Predicting Risk of Venous Thromboembolism in Multiple Myeloma: The Impede VTE Score

Patient Treatment Preferences for Relapsed/Refractory Multiple Myeloma: Are Patients Willing to Trade Off Efficacy for Tolerability?

Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Understanding the Preferences of Patients and Caregivers for Relapsed/Refractory Multiple Myeloma Treatment: A Mixed-Mode Patient-Centric Approach

Determinants of Hematology-Oncology Trainee's Post-Fellowship Career Pathways with a Focus on Non-Malignant Hematology

Relapsed or Refractory Multiple Myeloma Patients Treated with Second-Line Carfilzomib and Categorized By Prior Exposure to Bortezomib: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only